Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis

Study Date Design Blind method Follow-up period Sample size, n Enrollment period Cell origin Delivery approach MSCs dose Placebo
Wang JA 2006 RCT NA 6 months 24 2002.1–2004.10 Autologous bone marrow Intracoronary injection (5.86 ± 2.36) × 105/ml × 30 ml NS
Heldman AW 2013 RCT Double-blind 12 months 30 NA Autologous bone marrow TESI NA Vehicle placebo
Zhao XF 2014 RCT NA 6 months 59 2010.12–2011.12 Allogeneic Umbilical cord Intracoronary injection NA NA
Mathiasen AB 2015 RCT Double-blind 6 months 60 NA Autologous bone marrow TESI (77.5 ± 67.9) × 10^6 PBS
Xiao W 2016 RCT NA 12 months 37 2010.3–2011.6 Autologous bone marrow Intracoronary injection (4.9 ± 1.7) × 108 NS
Butler J 2016 RCT Single-blind 6 months 22 2014.6–2016.4 Autologous bone marrow Intravenous injection 1 × 106/kg LRS
Perin 2015 RCT Single-blind 12 months 60 2008.8–2010.6 Allogeneic bone marrow TESI 25/50/75 × 106 NA
Bartolucci J 2017 RCT Double-blind 12 months 30 2012.12–2014.6 Allogeneic Umbilical cord Intravenous injection 1 × 106/kg Autologous plasma
Bartunek J 2017 RCT Double-blind 39 weeks 271 2012.12–2015.7 Autologous bone marrow TESI NA NA
  1. RCT randomised controlled trial, TESI transendocardial stem cell injection, LRS lactate Ringer solution, NS normal saline, PBS phosphate buffer saline, NA not available